By Deena Beasley and Julie Steenhuysen
June 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
Gilead said the drug will be sold under the brand name Yeztugo.
(Reporting by Deena Beasley in Los Angeles and Julie Steenhuysen in Chicago; Editing by Bill Berkrot and Alan Barona)
((deena.beasley@thomsonreuters.com; 213 955 6746; Reuters Messaging: deena.beasley.thomsonreuters.com@reuters.net))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.